Gufic Biosciences Limited (GUFICBIO) AI Stock Analysis

• Market Cap: ₹29.41B
• Dividend Yield: 0.03%
• Average Volume (3M): 2.36K
• Price to Earnings (P/E): 67.8
• Beta (1Y): 0.77
• Revenue Growth: 7.78%
• EPS Growth: -34.68%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.24
• Shares Outstanding: 100,282,510
• 10 Day Avg. Volume: 2,111
• 30 Day Avg. Volume: 2,356
• PEG Ratio: -2.39
• Price to Book (P/B): 5.63
• Price to Sales (P/S): 4.13
• P/FCF Ratio: 124.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹304.00 ▼(-10.10% Downside)
• Action: Reiterated Date: 11/22/25
• Date: Action: Reiterated 11/22/25

Gufic Biosciences' overall stock score is primarily influenced by its strong financial performance, despite challenges in cash flow and debt management. Technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Revenue Growth Trend

Consistent top-line expansion across 2020–2025 reflects sustained demand for the company's formulations and supports steady scale advantages. Durable revenue growth underpins capacity utilization, long-term commercial relationships, and provides a base for reinvesting in manufacturing and product diversification.

Margin Sustainability

Stable gross and EBIT margins point to structural operational efficiency—likely driven by manufacturing scale and control over input costs. This margin resilience supports cash flow generation potential and competitive pricing flexibility over the medium term, aiding profitability even amid volume shifts.

Equity Base / Balance Sheet Stability

Rising shareholders' equity and a healthy equity ratio indicate improving capitalization and a buffer against shocks. A stronger equity base enhances financial flexibility for capex or capacity expansion and reduces bankruptcy risk, supporting strategic investments and long-term operational continuity.

Negative Factors

Elevated Leverage

A moderately high debt-to-equity level raises refinancing and interest-rate sensitivity over the medium term. Persistent leverage can constrain investment choices, increase fixed obligations during downturns, and heighten credit risk, requiring disciplined cash generation and liability management to avoid structural strain.

Cash Flow Variability

Volatile conversion of earnings to cash suggests working capital swings or timing of collections and payables, undermining reliable internal funding for growth. Periodic negative free cash flow limits ability to deleverage, sustain capex, or fund product launches without external financing, raising execution risk.

Profitability Volatility

Marked EPS decline and fluctuating net margins signal inconsistent bottom-line performance despite sales growth. This volatility may stem from mix shifts, cost pressures, or one-off items and complicates forecasting, investor confidence, and the firm's ability to consistently reinvest or return capital over the medium term.

Gufic Biosciences Limited Business Overview & Revenue Model

Company Description

Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.

How the Company Makes Money

Gufic Biosciences primarily makes money by selling pharmaceutical products, with revenue generated from the manufacture and commercialization of finished formulations. Key revenue streams typically include: (1) Domestic formulations: sales of branded and/or generic medicines to hospitals, healthcare providers, and pharmaceutical distribution channels in India, where demand is driven by therapy-area presence and market reach. (2) Exports/international business: sales of formulations to customers outside India, which may include product supply to overseas distributors or institutional buyers, and can be influenced by regulatory approvals in destination markets. (3) Contract manufacturing/third-party manufacturing: manufacturing pharmaceuticals for other companies under contract or for their brands, monetized through supply agreements and manufacturing margins. (4) Product mix and capacity utilization: earnings are influenced by the company’s ability to scale manufacturing, maintain quality compliance, and sell higher-value dosage forms (such as injectables) where manufacturing complexity can support better realization. Specific major partnerships, customer concentration, or segment-level revenue breakdowns: null.

Gufic Biosciences Limited Financial Statement Overview

Summary

Gufic Biosciences shows strong revenue growth and operational efficiency, but faces challenges with fluctuating net income and inconsistent cash flow. The balance sheet is stable, though the high debt-to-equity ratio requires careful management.

Income Statement

Gufic Biosciences has demonstrated strong revenue growth over the years, with a notable increase in total revenue from 2020 to 2025. The gross profit margin and EBIT margin are solid, indicating efficient cost management and operational effectiveness. However, the net profit margin has shown some fluctuations, suggesting potential volatility in net income performance.

Balance Sheet

The company's balance sheet indicates a relatively stable equity position with a consistent increase in stockholders' equity. However, the debt-to-equity ratio is moderately high, which may pose risks if not managed carefully. The equity ratio shows a healthy proportion of equity in the capital structure, enhancing financial stability.

Cash Flow

Gufic Biosciences exhibits inconsistent free cash flow performance, with notable fluctuations in free cash flow growth rates. The operating cash flow to net income ratio shows variability, suggesting challenges in converting income into cash flow. Despite periods of negative free cash flow, recent improvements indicate potential for recovery.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.74B	8.20B	8.07B	6.91B	7.79B	4.88B
Gross Profit	4.41B	2.97B	4.07B	3.51B	3.56B	2.31B
EBITDA	1.37B	1.38B	1.48B	1.37B	1.48B	857.85M
Net Income	569.19M	696.50M	861.36M	797.05M	958.40M	442.32M
Balance Sheet
Total Assets	12.71B	11.69B	10.93B	8.61B	5.21B	3.92B
Cash, Cash Equivalents and Short-Term Investments	880.79M	290.22M	11.37M	286.02M	116.08M	62.01M
Total Debt	3.69B	3.36B	3.33B	3.34B	643.87M	615.37M
Total Liabilities	6.40B	5.68B	5.60B	5.13B	2.52B	2.19B
Stockholders Equity	6.31B	6.01B	5.33B	3.48B	2.69B	1.73B
Cash Flow
Free Cash Flow	434.82M	270.96M	-1.20B	-2.14B	187.86M	748.51M
Operating Cash Flow	591.15M	1.03B	-74.57M	-265.87M	1.06B	872.51M
Investing Cash Flow	-152.90M	-717.09M	-1.02B	-1.91B	-945.89M	-66.93M
Financing Cash Flow	150.53M	-163.26M	823.81M	2.34B	-62.44M	-786.18M

Gufic Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 338.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Neutral. The current price of 338.15 is above the 20-day moving average (MA) of 284.66, above the 50-day MA of 300.17, and below the 200-day MA of 342.48, indicating a neutral trend. The MACD of -2.31 indicates Negative momentum. The RSI at 51.13 is Neutral, neither overbought nor oversold. The STOCH value of 75.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GUFICBIO.

Gufic Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IOLCP	60 Neutral	₹21.38B	29.38	―	0.97%	5.74%	16.06%
GUFICBIO	57 Neutral	₹29.41B	67.80	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹20.31B	20.54	―	0.49%	-0.29%	-29.04%
HIKAL	55 Neutral	₹20.47B	-118.51	―	0.58%	-6.72%	-86.26%
ORCHPHARMA	54 Neutral	₹26.19B	-76.20	―	―	-9.23%	-56.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	49 Neutral	₹17.45B	-18.14	―	0.08%	-2.81%	-444.69%

Gufic Biosciences Limited Corporate Events

Gufic Biosciences Settles SEBI Compliance Penalties Over Independent Director Appointment

Gufic Biosciences has disclosed that stock exchanges BSE and NSE imposed monetary penalties for alleged non-compliance with SEBI rules governing the appointment of independent directors over the age of 75. The issue relates to the appointment of Kamal Kishore Seth as an additional non-executive independent director without prior shareholder approval via special resolution.

The company had applied for a waiver of these penalties but BSE rejected the request, prompting full payment of the dues. Gufic has now settled all outstanding penalties for the June and September 2024 quarters, removing an overhang of regulatory uncertainty around this specific corporate governance matter for investors and exchanges.

Gufic Biosciences to Appeal GST Penalty Order, Sees No Material Impact

Gufic Biosciences Limited has disclosed that it received an order from the Office of the Superintendent CGST, Ghaziabad, imposing penalties totaling about Rs 15.64 lakh for alleged excess input tax credit claims and short payment of GST for financial years 2018-19 to 2022-23. The company plans to appeal the order and, based on its assessment and legal advice, does not expect any material impact on its financial operations or other activities, suggesting limited immediate implications for shareholders and business continuity.